Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Arif Hussain
Observed name:
A. Hussain
Institutions:
University of Maryland, Baltimore,
University of Maryland Medical Center,
Baltimore VA Medical Center,
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Observed institutions:
University of Maryland, Baltimore,
University of Maryland Medical Center,
Baltimore VA Medical Center,
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
ORCID:
0000-0001-8485-4406
Observed ORCID:
0000-0001-8485-4406
OpenAlex ID:
A5006485711
Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer
2026
·
Susan F. Slovin
, Xin Gao
, et al.
·
Clinical Cancer Research
·
29
Regulation of androgen receptor expression by enhancer elements in prostate cancer
2026
·
Sudeep Khadka
, Hee-Young Jeon
, et al.
·
Experimental & Molecular Medicine
·
5
PDF
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study
2026
·
Jose Luis Perez-Gracia
, Begoña Mellado
, et al.
·
Journal for ImmunoTherapy of Cancer
·
3
870 A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (MCRPC)
2014
·
D. Petrylak
, D.C. Smith
, et al.
·
European Urology Supplements
·
3
Abstract 7247: BPTF regulates androgen receptor activity in prostate cancer
2026
·
Hee-Young Jeon
, Sudeep Khadka
, et al.
·
Cancer Research
Abstract 3599: MYC exon 3 DNA methylation in peripheral blood and the risk of aggressive prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial
2026
·
Patricia A. Erickson
, Lauren M. Hurwitz
, et al.
·
Cancer Research
Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions
2026
·
Xiaolei Shi
, Safiullah Rifai
, et al.
·
Current Opinion in Oncology
Circulating tumor DNA (ctDNA) dynamics in bone-dominant metastatic castration resistant prostate cancer (mCRPC) treated with radium-223 with or without olaparib: Biomarker analyses from the multicenter, randomized, phase 2, investigator-initiated COMRADE trial.
2026
·
Rana R. McKay
, Russell William Madison
, et al.
·
Journal of Clinical Oncology
PDF
Phase 1/2 OMAHA-U01 substudy 01A: Oral CYP11A1 inhibitor opevesostat alone or in combination with other therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
2026
·
Arif Hussain
, Fred Saad
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
9
Citation count:
40
H-index:
3
I10-index:
1
Year
Topic
Type